Aredia, Zometa Monitoring Class Falls Short of Typicality Requirement

NASHVILLE, Tenn. - A federal judge has rejected an effort by plaintiffs in the Aredia and Zometa MDL to certify a medical monitoring class of patients at an increased risk of developing osteonecrosis of the jaw as a result of taking the drugs. In re Aredia and Zometa Products Liability Litigation, 06-MD-1760 (M.D. Tenn.).

Judge Todd J. Campbell of the U.S. District Court for the Middle District of Tennessee said Oct. 10 that the massive, multi-state proposed class failed Rule 23's typicality requirement in that it has too many individual legal and factual issues, which preclude certification.

The plaintiffs …